TL;DR: A 2026 systematic review in Future Science OA found early medication evidence for online behavioral addictions, but the 20 included studies were mostly small, male-heavy, and short-term. Key Findings Medication evidence stayed early: The review found small, mixed pharmacotherapy signals across 20 online behavioral addiction studies. Clinical groups stayed small: The 1,016 total participants …
TL;DR: A 2026 real-world study in Journal of Clinical Sleep Medicine found that glucagon-like peptide-1 receptor agonist use was associated with lower 3-year cardiovascular-event risk in adults with obesity and obstructive sleep apnea. Key Findings 18,523 matched pairs: Propensity matching compared GLP-1 receptor agonist users with similar non-users who had obesity and obstructive sleep apnea. …
TL;DR: A 2026 crossover study in Clinical Physiology and Functional Imaging found that adding electrical muscle stimulation to low-intensity resistance exercise improved inhibitory control in young men, while stimulation alone showed a delayed 15-minute benefit. Key Findings 17 young men: Participants completed low-intensity resistance exercise, electrical muscle stimulation alone, and combined low-intensity exercise plus stimulation …
TL;DR: A 2026 pilot randomized trial in Nursing in Critical Care found that an 8-week home-based program combining exercise with computerized cognitive training was feasible in 36 ICU survivors and produced larger reductions in patient-reported post-intensive care syndrome severity than attention control, while exploratory cognitive and quality-of-life effect sizes generally favored the combined program over …
TL;DR: A 2026 review in International Journal of Nanomedicine argued that depression nanomedicine should move beyond blood-brain-barrier delivery alone and be judged by target engagement, neuroimmune-barrier-plasticity effects, safety, manufacturability, and patient stratification. Key Findings Mechanism-centered review: The paper organized depression nanomedicine around neuroinflammation, blood-brain-barrier dysfunction, oxidative stress, and impaired neuroplasticity. 3 strategy groups: The review …
TL;DR: A 2026 study in European Journal of Nuclear Medicine and Molecular Imaging found that semiquantitative [123I]FP-CIT SPECT metrics, especially caudate-to-putamen and sensorimotor-to-limbic ratios, helped distinguish Parkinson’s disease from atypical parkinsonian syndromes, while a random forest classifier remained more useful as decision support than as a standalone diagnosis. Key Findings 706-patient cohort: The study included …
TL;DR: A 2026 study in European Archives of Psychiatry and Clinical Neuroscience linked sustained quetiapine treatment with better high-working-memory cognitive performance in schizophrenia spectrum disorder, but the genetic tests did not support the proposed remyelination-moderation mechanism. Key Findings 166 matched pairs: The extended PsyCourse analysis included 166 quetiapine-treated schizophrenia-spectrum patients and 166 age- and sex-matched …
TL;DR: A 2026 real-world cohort study in The Journal of Prevention of Alzheimer’s Disease found that lecanemab-treated Alzheimer’s patients had lower Neuropsychiatric Inventory scores over follow-up, and 6-month symptom reductions were associated with regional amyloid-beta positron emission tomography (PET) clearance. Key Findings 144 treated patients: The cohort included people with Alzheimer’s-related mild cognitive impairment or …
TL;DR: A 2026 randomized trial in Physiotherapy Research International found that adding active 5 Hz repetitive transcranial magnetic stimulation (rTMS) over the dorsolateral prefrontal cortex to dual-task stroke rehabilitation produced larger gains in Timed Up-and-Go performance, balance confidence, and cognitive screening than sham stimulation plus the same training. Key Findings Small randomized trial: The study …
TL;DR: A 2026 case study in Biomedical Reports described a 28-year-old woman with bipolar II disorder whose stable subclinical counting compulsion worsened and expanded into new obsessive-compulsive symptoms within 3 days of starting cariprazine, then returned near baseline within 7 days after the drug was stopped. Key Findings Single case report: The source described one …
